Cargando…

Author Correction: Synthesis and comparative evaluation of (177)Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes

Detalles Bibliográficos
Autores principales:	Sharma, Amit Kumar, Sharma, Rohit, Vats, Kusum, Sarma, Haladhar Dev, Mukherjee, Archana, Das, Tapas, Satpati, Drishty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643342/ https://www.ncbi.nlm.nih.gov/pubmed/36347949 http://dx.doi.org/10.1038/s41598-022-23594-y

Ejemplares similares

Synthesis and comparative evaluation of (177)Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes
por: Sharma, Amit Kumar, et al.
Publicado: (2022)

Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations with (177)Lu-Acridine
por: Ghosh, Subhajit, et al.
Publicado: (2020)

Author Correction: A Microfluidic Platform to design Multimodal PEG - crosslinked Hyaluronic Acid Nanoparticles (PEG-cHANPs) for diagnostic applications
por: Tammaro, Olimpia, et al.
Publicado: (2020)

Author Correction: mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human Growth Hormone (rhGH)
por: Ghasemi, Rohollah, et al.
Publicado: (2019)

Preparation of (177)Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House
por: Guleria, Mohini, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Author Correction: CRISPR activation screen identifies TGFβ-associated PEG10 as a crucial tumor suppressor in Ewing sarcoma
por: Saratov, Vadim, et al.
Publicado: (2022)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

The Peg Formboards
por: Wallin, J. E. Wallace
Publicado: (1918)

Pegging Away
Publicado: (1892)

Design, Synthesis, and Comparison of PLA-PEG-PLA and PEG-PLA-PEG Copolymers for Curcumin Delivery to Cancer Cells
por: Rostami, Neda, et al.
Publicado: (2023)

Oxytocin receptor is regulated by Peg3
por: Frey, Wesley D., et al.
Publicado: (2018)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Expression of PEG11 and PEG11AS transcripts in normal and callipyge sheep
por: Bidwell, Christopher A, et al.
Publicado: (2004)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
por: Kozma, Gergely Tibor, et al.
Publicado: (2023)

PEGGING MITOCHONDRIAL POSITION
por: Robinson, Richard
Publicado: (2008)

Protocol for generation and regeneration of PEG-passivated slides for single-molecule measurements
por: Paul, Tapas, et al.
Publicado: (2022)

Peg Biology: Deciphering the Molecular Regulations Involved During Peanut Peg Development
por: Kumar, Rakesh, et al.
Publicado: (2019)

Development of (177)Lu-phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2013)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Preventing postoperative abdominal adhesions in a rat model with PEG-PCL-PEG hydrogel
por: Yang, Bing, et al.
Publicado: (2012)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model
por: Shim, Kyuhwan, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

Effect of Short PEG on Near-Infrared BODIPY-Based Activatable Optical Probes
por: Inagaki, Fuyuki F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4cka8du3lcjks45saq6rm0sril